

Supplementary Figure Legend

Supplementary Figure S1. Progression-free survival in the study population and subgroup of patients with del(17p) and/or *TP53* mutations while participating in the DUO study (ofatumumab before crossover).

Supplementary Figure S2. Progression-free survival in specified patient subgroups: **A**, del(11q); **B**, trisomy 12; and **C**, bulky disease.

Supplementary Figure S3. Overall survival in the study population.